Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 3
1995 3
1996 2
1997 4
1998 8
1999 2
2000 10
2001 12
2002 11
2003 10
2004 13
2005 12
2006 22
2007 25
2008 24
2009 16
2010 15
2011 22
2012 20
2013 15
2014 8
2015 6
2016 3
2017 11
2018 7
2019 6
2020 7
2021 5
2022 6
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: defitito
Page 1
Denileukin Diftitox.
[No authors listed] [No authors listed] 2017 Dec 27. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Dec 27. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643755 Free Books & Documents. Review.
Denileukin diftitox is a recombinant fusion protein of human interleukin-2 (IL-2) attached to diphtheria toxin fragments A and B that is used as an antineoplastic agent to treat cutaneous T cell lymphomas that express IL-2 receptors. High doses of denileukin diftito …
Denileukin diftitox is a recombinant fusion protein of human interleukin-2 (IL-2) attached to diphtheria toxin fragments A and B that …
Denileukin diftitox.
Figgitt DP, Lamb HM, Goa KL. Figgitt DP, et al. Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. doi: 10.2165/00128071-200001010-00008. Am J Clin Dermatol. 2000. PMID: 11702307 Review.
Denileukin diftitox is a novel interleukin-2 receptor (IL-2R)-targeted diphtheria toxin. ...Vascular leak syndrome has occurred during denileukin diftitox therapy. Antibody titers to denileukin diftitox occur in most patients after treatment but the presence …
Denileukin diftitox is a novel interleukin-2 receptor (IL-2R)-targeted diphtheria toxin. ...Vascular leak syndrome has occurred durin …
Denileukin Diftitox.
[No authors listed] [No authors listed] 2024 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33355734 Free Books & Documents. Review.
Denileukin diftitox is no longer marketed in the US. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. ...
Denileukin diftitox is no longer marketed in the US. Most sources consider breastfeeding to be contraindicated during maternal antine …
Denileukin diftitox: a novel immunotoxin.
Manoukian G, Hagemeister F. Manoukian G, et al. Expert Opin Biol Ther. 2009 Nov;9(11):1445-51. doi: 10.1517/14712590903348135. Expert Opin Biol Ther. 2009. PMID: 19817678 Review.
OBJECTIVE: To review FDA approved and other potential uses of Ontak, denileukin diftitox. METHODS: Information was obtained via the internet and a journal literature review. ...CONCLUSION: There are many potential uses for denileukin diftitox, in both malignant and …
OBJECTIVE: To review FDA approved and other potential uses of Ontak, denileukin diftitox. METHODS: Information was obtained via the i …
Monoclonal Antibodies.
Geskin LJ. Geskin LJ. Dermatol Clin. 2015 Oct;33(4):777-86. doi: 10.1016/j.det.2015.05.015. Dermatol Clin. 2015. PMID: 26433849 Free article. Review.
Denileukin diftitox: a concise clinical review.
Eklund JW, Kuzel TM. Eklund JW, et al. Expert Rev Anticancer Ther. 2005 Feb;5(1):33-8. doi: 10.1586/14737140.5.1.33. Expert Rev Anticancer Ther. 2005. PMID: 15757436 Review.
Denileukin diftitox (DAB389IL-2; Ontak) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. ...This article will review the clinical trials leading to the approval of …
Denileukin diftitox (DAB389IL-2; Ontak) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the …
Cancer immunotherapy.
Dillman RO. Dillman RO. Cancer Biother Radiopharm. 2011 Feb;26(1):1-64. doi: 10.1089/cbr.2010.0902. Cancer Biother Radiopharm. 2011. PMID: 21355777 Review.
These include the nonspecific immune stimulants BCG and levamisole; the cytokines interferon-alpha and interleukin-2; the monoclonal antibodies rituximab, ofatumumab, alemtuzumab, trastuzumab, bevacizumab, cetuximab, and panitumumab; the radiolabeled antibodies Y-90 ibritumomab t …
These include the nonspecific immune stimulants BCG and levamisole; the cytokines interferon-alpha and interleukin-2; the monoclonal antibod …
Clinical experience with denileukin diftitox (ONTAK).
Foss F. Foss F. Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. doi: 10.1053/j.seminoncol.2005.12.017. Semin Oncol. 2006. PMID: 16516670 Review.
Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. ...This article examines the clinical profile and potential benefits of denileukin di …
Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria tox …
Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Wong BY, Gregory SA, Dang NH. Wong BY, et al. Cancer Invest. 2007 Sep;25(6):495-501. doi: 10.1080/07357900701360096. Cancer Invest. 2007. PMID: 17882663 Review.
Denileukin diftitox (DAB(389)IL-2; Ontak) is a cytotoxic fusion protein designed to target cells expressing the receptor for interleukin-2 (IL-2). It has been approved for treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant c …
Denileukin diftitox (DAB(389)IL-2; Ontak) is a cytotoxic fusion protein designed to target cells expressing the receptor for interleu …
Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
Walker PL, Dang NH. Walker PL, et al. Clin J Oncol Nurs. 2004 Apr;8(2):169-74. doi: 10.1188/04.CJON.169-174. Clin J Oncol Nurs. 2004. PMID: 15108419 Review.
Although numerous regimens have demonstrated efficacy in the treatment of NHL, some subtypes of lymphomas generally are not curable. The recent development of targeted therapies such as denileukin diftitox (Ontak, Ligand Pharmaceuticals, Inc., San Diego, CA) has resulted i …
Although numerous regimens have demonstrated efficacy in the treatment of NHL, some subtypes of lymphomas generally are not curable. The rec …
290 results